p53 Mutations, c-myc and bcl-2 Rearrangements in Human Non-Hodgkin's Lymphoma Cell Lines

References

• Weinberg R.A. Oncogenes, antioncogenes and the molecular basis of multistep carcinogenesis. Cancer Research 1989; 49: 3713–3721
   PubMed Web of Science ®Google Scholar
• Hunter T. Cooperation between oncogenes. Cell 1991; 64: 249–270
   Google Scholar
• Gaidano G., Ballerini P., Gong J.Z., Inghirami G., Neri A., Newcomb E.W., Magrath I.T., Knowlers D.M., Dalla-Favera R. p53 mutations in human lymphoid malignancies: Association with Burkitt lymphoma and chronic lymphocytic leukemia. Proc. Natl. Acad. Sci. USA 1991; 88: 5413–5417
   PubMed Web of Science ®Google Scholar
• Farell P.J., Allan G.J., Shanahan F., Vousden K.H., Crook T. pS3 is frequently mutated in Burkitt's lymphoma cell lines. E.M.B.O.J. 1991; 1: 2879–2887
   Google Scholar
• Wiman K.G., Magnusson K.P., Ramqvist T., Klein G. Mutant p53 detected in a majority of Burkitt's lymphoma cell lines by monoclonal antibody PAb240. Oncogene 1991; 6: 1633–1639
   PubMed Web of Science ®Google Scholar
• Adams J.M., Cory S. Oncoeene co-operation in leukemoenesis. Cancer Surveys 1992; 15: 119–141
   PubMedGoogle Scholar
• Strasser A., Harris A.W., Bath M.L., Cory S. Novel primitive lymphoid tumors induced in transgenic mice by cooperation between myc and bcl-2. Nature 1990; 348: 331–333
   PubMed Web of Science ®Google Scholar
• McDonnell T.J., Korsmeyer S.J. Progression from lymphoid hyperplasia to high-grade malignant lymphoma in mice transgenic for the t(14;18). Nature 1991; 349: 254–256
   PubMed Web of Science ®Google Scholar
• Cannon J.V., Greaves R., Iggo R., Lane D.P. Activating mutations in p53 produce a common conformational effect. A monoclonal antibody specific for mutant form. E.M. B.O.J. 1990; 9: 1595–1602
   PubMed Web of Science ®Google Scholar
• Tweeddale M.E., Lim B., Jamal N., Robinson J., Zalcberg J., Lockwood G., Minden M.D., Messner H.A. The presence of clonogenic cells in high-grade malignant lymphoma: a prognostic factor. Blood. 1987; 69: 1307–1314
   PubMed Web of Science ®Google Scholar
• Chang H., Yee C., Wang X.H., Addy L., Meharchand J., Minden M.D., Messner H.A. A human lymphoma cell line with multiple immunoglobulin rearrangements. J. Clin. Invest. 1992; 89: 1014–1020
   PubMed Web of Science ®Google Scholar
• Chang H., Jamal N., Wang X.H., Minden M.D., Messner H.A. Constitutive production of the Interleukins IL-5 and IL-6 by the lymphoma cell line OCI-LY 17 derived from a patient with malignant lymphoma and hypereosinophilia. Leukemia and Lymphoma 1992; 8: 97–107
   PubMed Web of Science ®Google Scholar
• Banks L., Matlashewski G., Crawford L. Isolation of human-p53-specific monoclonal antibodies and heir use in the studies of human p53 expression. Eur. J. Biochem. 1986; 159: 529–534
   PubMedGoogle Scholar
• Harlow E., Crawford L.V., Pim D.C., Williamson N.M. Monoclonal antibodies specific for Simian virus 40 tumor antigenes. J. Virol. 1981; 39: 861–869
   PubMed Web of Science ®Google Scholar
• Dalla-Favera R., Gelmann Martinotti E.P., Franchini S.G., Papas Gallo R. C T.S., Wong-Staal F. Cloning and characterization of different human sequences related to oncogene (v-myc) of avian myelocytomatosis virus (mc29). Proc, Nail. Acad, Sci. USA 1982; 79: 6497–6501
   PubMed Web of Science ®Google Scholar
• Matlashewski G.J., Tuck S., Pim D., Lamb P., Schneider J., Crawford L.V. Primary structure polymorphism at amino acid residue 72 of human p53. Mol. Cell. Biol 1987; 7: 961–963
   PubMed Web of Science ®Google Scholar
• Clery M.L., Sklar S. Nucleotide sequence of a t(14; 18) chromosomal breakpoint in follicular lymphoma and demonstration of a breakpoint—cluster region near a transcriptionally active locus on chromosome 18. Proc. Natl. Accid, Sci. USA 1985; 82: 7439–7443
   PubMed Web of Science ®Google Scholar
• Slingerland J.M., Minden M.D., Benchimol S. Mutation of the p53 gene in human acute myelogeneous leukemia. Blood 1991; 77: 1500–1507
   PubMed Web of Science ®Google Scholar
• Chairgwin J.M., Przybyla MacDonald R. J A.E., Rutter W.J. Isolation of biologically active ribonucleic acid from sources enriched in ribonuclease. Biochemistry 1979; 18: 5294–5299
   PubMed Web of Science ®Google Scholar
• Lehmann E.L. Nonparametrics: Statistical methods based on ranks. Holdon-day, San Francisco 1975
   Google Scholar
• Chang H., Benchimol S., Minden M.D., Messner H.A. Alterations of p53 and c-myc in the clonal evolution of malignant lymphoma. Blood 1994; 83: 452–459
   PubMed Web of Science ®Google Scholar
• Yee C., Biondi A., Wang X.H., Iscove N.N., De Sousa J., Aarden L.A., Wong G.G., Clark S.C., Messner H.A., Minden M.D. A possible autocrine role for Interleukin 6 in two lymphoma cell lines. Blood 1989; 74: 798–804
   PubMed Web of Science ®Google Scholar
• Farrgia MM, Duan L.J., Reis M.D., Ngan B.Y., Berinstein N.L. Alterations of the p53 tumor suppressor gene in diffuse large cell lymphomas with translocations of the c-myc and bcl-2 proto-oncogenes. Blood. 1994; 83: 191–198
   PubMed Web of Science ®Google Scholar
• Lavigeur A., Maltby V., Mock D., Rossant J., Pawson T., Bernstein A. High incidence of lung, bone and lymphoid tumors in transgenic mice overexpressing mutant alleles of the p53 oncogene. Mol. Cell, Biol. 1989; 9: 3982–3991
   PubMed Web of Science ®Google Scholar
• Marcu K.B., Bossone S.A., Patel A.J. Myc function and regulation. Annu, Rev. Biochem. 1992; 61: 809–860
   PubMed Web of Science ®Google Scholar
• Askew D.S., Ashmun R.A., Simmons B.C., Cleveland J.L. Constitutive c-myc expression in an IL-3-dependent myeloid cell line suppresses cell cycle arrest and accelerates apoptosis. Oncogene. 1991; 6: 1915–1922
   PubMed Web of Science ®Google Scholar
• Evans G.I., Wyllie A.H., Gilbert C.S., Littlewood T.D., Land H., Brooks M., Waters C.M., Penn L.Z., Hancock D.C. Induction of apoptosis in fibroblasts by c-myc protein. Cell 1992; 69: 119–128
   PubMed Web of Science ®Google Scholar
• Wang Y., Ramquist T., Szekely L., Axelson H., Klein G., Wiman K.G. Reconstitution of wild-type p53 expression triggers apoptosis in a p53-negative v-myc retrovirus- induced T-cell lymphoma line. Cell Growth & Differ. 1993; 4: 467–473
   PubMedGoogle Scholar
• Miller C.W., Aslo A., Tsay C., Slamon D., Ishizaki K., Toguchida T., Yamamuro T., Lampkin B., Koeffler H.P. Frequency and structure of p53 rearrangements in human osteosarcoma. Cancer Res. 1990; 50: 7950–7954
   PubMed Web of Science ®Google Scholar
• Masuda H., Miller C., Koeffler H.P., Battifora H., Cline M.J. Rearrangement of the p53 gene in human osteogenic sarcomas. Proc., Natl Acad, Sci. USA 1987; 84: 7716–7719
   PubMed Web of Science ®Google Scholar
• Lee J.M., Bernstein A. p53 mutations increase resistance to ionizing radiation. Proc, Natl., Acad Sci. USA 1993; 90: 5742–5746
   PubMed Web of Science ®Google Scholar
• Lotem J., Sachs L. Regulation by bcl-2. c-myc and p53 susceptibility to induction of apoptosis by heat shock and cancer chemotherapy compounds in differentiation-competent and -defective myeloid leukemic cells. Cell Growth Differ. 1993; 4: 41–47
   PubMedGoogle Scholar
• Schmidt-Wolf I.G.H., Negri R.S., Kiem H.P., Blume K.G., Weisman I.L. Use of a SCID mouse/human lymphoma model to evaluate cytokine-reduced killer cells with potential anti-tumor cell activity. J. Exp. Med. 1991; 174: 139–149
   PubMed Web of Science ®Google Scholar
• Chang H., Leder S., Cook V.A., Patterson B., Dosch M., Minden M.D., Messner H.A. Growth of human lymphoma cells in SCID mice. Leukemia and Lymphoma. 1992; 8: 129–136
   PubMed Web of Science ®Google Scholar